<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, June 5, 2020 (HealthDay News) — Tumor biomarkers are independently associated with measures of heart failure severity and outcomes, according to a study published online May 5 in the Journal of Internal Medicine<\/i>.<\/p>\n
Canxia Shi, from the University of Groningen in the Netherlands, and colleagues analyzed data from 2,079 patients participating in the BIOSTAT-CHF cohort, with measurements of six established tumor biomarkers: CA125, CA15-3, CA19-9, CEA, CYFRA 21-1, and AFP.<\/p>\n
The researchers found that during a median 21 months of follow-up, 27 percent of patients reached the primary end point of all-cause mortality. There was a positive association between CA125, CYFRA 21-1, CEA, and CA19-9 levels with N-terminal pro-B-type natriuretic peptide (NT-proBNP) quartiles. After adjusting for BIOSTAT risk model (age, blood urea nitrogen, NT-proBNP, hemoglobin, and beta blocker), CA125, CYFRA 21-1, CEA, and CA19-9 levels were associated with an increased risk for all-cause mortality (hazard ratios, 1.17, 1.45, 1.19, and 1.10, respectively). Except for AFP, all tumor biomarkers were significantly associated with secondary end points, including a composite of all-cause mortality and heart failure hospitalization, heart failure hospitalization, cardiovascular (CV) mortality, and non-CV mortality. CYFRA 21-1 (0.64) had a noninferior area under the curve (AUC) versus NT-proBNP (0.68) for all-cause mortality. The model’s ability to predict all-cause mortality was improved with a combination of CYFRA 21-1 and NT-proBNP (AUC, 0.71) versus NT-proBNP alone.<\/p>\n
“This demonstrates that pathophysiological pathways sensed by these tumor biomarkers are also dysregulated in heart failure,” the authors write.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n